{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shoham S"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","NIAID NIH HHS","Moriah Fund","NIH","Mental Wellness Foundation","National Institute of Allergy and Infectious Diseases","Division of Intramural Research NIAID NIH","HealthNetwork Foundation","Octapharma","JPEO-CBRND","Shear Family Foundation","DHA"],"pagination":["e477-e486"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9129191"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["76(3)"],"pubmed_abstract":["<h4>Background</h4>The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.<h4>Methods</h4>This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.<h4>Results</h4>In total, 18"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial."],"pmcid":["PMC9129191"],"funding_grant_id":["U24 TR001609","R01 AI152078","UL1 TR001409","UL1TR003098","UL1 TR001414","3R01AI152078-01S1","U24TR001609-S3"],"pubmed_authors":["Huaman MA","Patel B","Hanley D","Lane K","Cluzet V","Ehrhardt S","Rausch W","Singleton JR","Park HS","Paxton JH","Petrini J","Cordisco ME","Jabs DA","Karlen N","Casadevall A","McBee N","Pekosz A","Kassaye SG","Gerber J","Bloch EM","Levine AC","Broderick P","Caputo CA","Merlo C","Zand M","Bowen A","Currier J","Shoham S","Blair PW","Cachay E","Shade DM","Hammel J","Thomas DL","Baksh S","Mosnaim G","Gebo K","Forthal D","Jedlicka A","Naeim A","Cruser D","Gniadek T","Zenilman JM","Klein S","Shapiro JR","Tobian AAR","Laeyendecker O","Sullivan DJ","Gawad AL","Meisenberg B","Anjan S","Sutcliffe C","Fukuta Y","Yarava A","Appel L","Lau B","Allen ES"],"additional_accession":[]},"is_claimable":false,"name":"Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.","description":"<h4>Background</h4>The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.<h4>Methods</h4>This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.<h4>Results</h4>In total, 18","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-09T15:34:46.544Z","creation":"2025-02-19T03:58:38.877Z"},"accession":"S-EPMC9129191","cross_references":{"pubmed":["35579509"],"doi":["10.1093/cid/ciac372"]}}